Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2018, Article ID 4524837, 11 pages
https://doi.org/10.1155/2018/4524837
Review Article

Does Rabbit Antithymocyte Globulin (Thymoglobuline®) Have a Role in Avoiding Delayed Graft Function in the Modern Era of Kidney Transplantation?

Department of Renal Transplantation, Fundació Puigvert, Barcelona, Spain

Correspondence should be addressed to Lluís Guirado; se.trevgiup-oicadnuf@odariugl

Received 12 April 2018; Accepted 20 June 2018; Published 12 July 2018

Academic Editor: Andreas Zuckermann

Copyright © 2018 Lluís Guirado. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. D. Irish, J. N. Ilsley, M. A. Schnitzler, S. Feng, and D. C. Brennan, “A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation,” American Journal of Transplantation, vol. 10, no. 10, pp. 2279–2286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Schold, E. Poggio, D. Goldfarb, L. Kayler, and S. Flechner, “Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States,” Transplantation, vol. 99, no. 6, pp. 1165–1171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Peräsaari, L. E. Kyllönen, K. T. Salmela, and J. M. Merenmies, “Pre-transplant donor-specific anti-human leukocyte antigen antibodies are associated with high risk of delayed graft function after renal transplantation,” Nephrology Dialysis Transplantation, vol. 31, no. 4, pp. 672–678, 2016. View at Google Scholar
  4. W. G. Yarlagadda, S. G. Coca, R. N. Formica, E. D. Poggio, and C. R. Parikh, “Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 1039–1047, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. I. E. Hall, P. P. Reese, M. D. Doshi et al., “Delayed graft function phenotypes and 12-month kidney transplant outcomes,” Transplantation, vol. 101, no. 8, pp. 1913–1923, 2017. View at Publisher · View at Google Scholar
  6. J. Gill, J. Dong, C. Rose, and J. S. Gill, “The risk of allograft failure and the survival benefit of kidney transplantation are complicated by delayed graft function,” Kidney International, vol. 89, no. 6, pp. 1331–1336, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Hart, J. M. Smith, M. A. Skeans et al., “OPTN/SRTR 2015 Annual Data Report: Kidney,” American Journal of Transplantation, vol. 17, supplement 1, pp. 21–116, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Lechevallier, B. Dussol, A. Luccioni et al., “Posttransplantation acute tubular necrosis: risk factors and implications for graft survival,” American Journal of Kidney Diseases, vol. 32, no. 6, pp. 984–991, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Perico, D. Cattaneo, M. H. Sayegh, and G. Remuzzi, “Delayed graft function in kidney transplantation,” The Lancet, vol. 364, no. 9447, pp. 1814–1827, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. R. Redfield, J. R. Scalea, T. J. Zens et al., “Predictors and outcomes of delayed graft function after living-donor kidney transplantation,” Transplant International, vol. 29, no. 1, pp. 81–87, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Butler and N. Hayde, “Impact of induction therapy on delayed graft function following kidney transplantation in mated kidneys,” Transplantation Proceedings, vol. 49, no. 8, pp. 1739–1742, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Chapal, F. Le Borgne, C. Legendre et al., “A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors,” Kidney International, vol. 86, no. 6, pp. 1130–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Nashan, M. Abbud-Filho, and F. Citterio, “Prediction, prevention, and management of delayed graft function: where are we now?” Clinical Transplantation, vol. 30, no. 10, pp. 1198–1208, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Gill, J. Dong, M. Eng, D. Landsberg, and J. S. Gill, “Pulsatile perfusion reduces the risk of delayed graft function in deceased donor kidney transplants, irrespective of donor type and cold ischemic time,” Transplantation, vol. 97, no. 6, pp. 668–674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Lodhi, K. E. Lamb, I. Uddin, and H. U. Meier-Kriesche, “Pulsatile pump decreases risk of delayed graft function in kidneys donated after cardiac death,” American Journal of Transplantation, vol. 12, no. 10, pp. 2774–2780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Bunnapradist and S. K. Takemoto, “Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants,” Transplantation Proceedings, vol. 37, no. 2, pp. 889–891, 2005. View at Publisher · View at Google Scholar
  17. G. Opelz, C. Unterrainer, C. Süsal, and B. Döhler, “Efficacy and safety of antibody induction therapy in the current era of kidney transplantation,” Nephrology Dialysis Transplantation, vol. 31, no. 10, pp. 1730–1738, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Summers, C. J. E. Watson, G. J. Pettigrew et al., “Kidney donation after circulatory death (DCD): state of the art,” Kidney International, vol. 88, no. 2, pp. 241–249, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Barba, J. J. Zudaire, J. E. Robles, D. Rosell, J. M. Berian, and I. Pascual, “Complications of kidney transplantation with grafts from expanded criteria donors,” World Journal of Urology, vol. 31, no. 4, pp. 893–899, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Young, S. N. Dixon, G. A. Knoll et al., “The Canadian experience using the expanded criteria donor classification for allocating deceased donor kidneys for transplantation,” Canadian Journal of Kidney Health and Disease, vol. 3, p. 15, 2016. View at Publisher · View at Google Scholar
  21. K. Hesse, E. Aitken, M. Clancy, and A. Vesey, “Expanded criteria donor and donation after circulatory death renal allografts in the West of Scotland: their place in the kidney allocation process,” The Surgeon, vol. 14, no. 3, pp. 136–141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Jiao, S. Liu, H. Liu, D. Cheng, Y. Cheng, and Y. Liu, “Hypothermic machine perfusion reduces delayed graft function and improves one-year graft survival of kidneys from expanded criteria donors: a meta-analysis,” PLoS ONE, vol. 8, no. 12, Article ID e81826, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. D. J. Taber, D. DuBay, J. W. McGillicuddy et al., “Impact of the new kidney allocation system on perioperative outcomes and costs in kidney transplantation,” Journal of the American College of Surgeons, vol. 224, no. 4, pp. 585–592, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. W. D. Irish, D. A. McCollum, R. J. Tesi et al., “Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients,” Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2967–2974, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. P. F. Halloran and L. G. Hunsicker, “Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA,” American Journal of Transplantation, vol. 1, no. 2, pp. 115–120, 2001. View at Google Scholar · View at Scopus
  26. C. Jeldres, H. Cardinal, A. Duclos et al., “Prediction of delayed graft function after renal transplantation,” Canadian Urological Association Journal, vol. 3, no. 5, pp. 377–382, 2009. View at Google Scholar · View at Scopus
  27. C. R. Parikh, I. E. Hall, R. S. Bhangoo et al., “Associations of perfusate biomarkers and pump parameters with delayed graft function and deceased donor kidney allograft function,” American Journal of Transplantation, vol. 16, no. 5, pp. 1526–1539, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Y. Koo, J. C. Jeong, Y. Lee et al., “Pre-transplant evaluation of donor urinary biomarkers can predict reduced graft function after deceased donor kidney transplantation,” Medicine, vol. 95, no. 11, Article ID e3076, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. B. W. M. Van Balkom, H. Gremmels, L. S. S. Ooms et al., “Proteins in preservation fluid as predictors of delayed graft function in kidneys from donors after circulatory death,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 5, pp. 817–824, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Malyszko, E. Lukaszyk, I. Glowinska, and M. Durlik, “Biomarkers of delayed graft function as a form of acute kidney injury in kidney transplantation,” Scientific Reports, vol. 5, Article ID 11684, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Mehrabi, Zh. A. Mood, M. Sadeghi et al., “Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. viii54–viiii60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Genestier, S. Fournel, M. Flacher, O. Assossou, J.-P. Revillard, and N. Bonnefoy-Berard, “Induction of fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins,” Blood, vol. 91, no. 7, pp. 2360–2368, 1998. View at Google Scholar · View at Scopus
  33. X. Préville, M. Flacher, B. LeMauff et al., “Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model,” Transplantation, vol. 71, no. 3, pp. 460–468, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. G. LaCorcia, M. Swistak, C. Lawendowski et al., “Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion,” Transplantation, vol. 87, no. 7, pp. 966–974, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M.-C. Michallet, X. Preville, M. Flacher, S. Fournel, L. Genestier, and J.-P. Revillard, “Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins,” Transplantation, vol. 75, no. 5, pp. 657–662, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Walther, A. Beiras-Fernandez, C. Csapo et al., “Influence of polyclonal antithymocyte globulins on the expression of adhesion molecules of isolated human umbilical vein endothelial cells,” Transplantation Proceedings, vol. 42, no. 5, pp. 1931–1934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Beiras-Fernandez, D. Chappell, C. Hammer, A. Beiras, B. Reichart, and E. Thein, “Impact of polyclonal anti-thymocyte globulins on the expression of adhesion and inflammation molecules after ischemia-reperfusion injury,” Transplant Immunology, vol. 20, no. 4, pp. 224–228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Beiras-Fernandez, D. Chappell, C. Hammer, and E. Thein, “Influence of polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury in a non-human primate model,” Transplant Immunology, vol. 15, no. 4, pp. 273–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Aiello, P. Cassis, M. Mister et al., “Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation,” Transplant International, vol. 24, no. 8, pp. 829–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. T. Becker, R. M. Hofmann, J. Yracheta, A. Friedl, and B. N. Becker, “Epithelial cell polarity and improved early outcomes in delayed graft function: a pilot study of polyclonal vs monoclonal antibodies,” Nephrology Dialysis Transplantation, vol. 19, no. 11, pp. 2886–2892, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. W. C. Goggins, M. A. Pascual, J. A. Powelson et al., “A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients,” Transplantation, vol. 76, no. 5, pp. 798–802, 2003. View at Publisher · View at Google Scholar
  42. T. R. McCune, D. G. Wombolt, T. V. Whelan, L. R. Thacker, and J. O. Colonna, “Vasodilatation vs. immunotherapy to prevent delayed graft function: delayed graft function as an indication of immune activation,” International Immunopharmacology, vol. 5, no. 1, pp. 85–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Bogetti, H. N. Sankary, T. M. Jarzembowski et al., “Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury,” Clinical Transplantation, vol. 19, no. 4, pp. 507–511, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Cicora, J. Roberti, N. Lausada et al., “Donor preconditioning with rabbit anti-rat thymocyte immunoglobulin ameliorates ischemia reperfusion injury in rat kidney transplantation,” Transplant Immunology, vol. 27, no. 1, pp. 1–7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. S. J. Patel, B. T. Duhart Jr., A. G. Krauss et al., “Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction,” Transplantation, vol. 86, no. 2, pp. 313–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. E. J. Hoorn, S. B. Walsh, J. A. McCormick, R. Zietse, R. J. Unwin, and D. H. Ellison, “Pathogenesis of calcineurin inhibitor–induced hypertension,” Journal of Nephrology, vol. 25, no. 3, pp. 269–275, 2012. View at Publisher · View at Google Scholar
  47. J. R. Chapman, “Chronic calcineurin inhibitor nephrotoxicity-lest we forget,” American Journal of Transplantation, vol. 11, no. 4, pp. 693–697, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. J. H. Tian, X. Wang, K. H. Yang, A. P. Liu, X. F. Luo, and J. Zhang, “Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials,” Transplantation Proceedings, vol. 41, no. 9, pp. 3671–3676, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. D. C. Brennan, J. A. Daller, K. D. Lake, D. Cibrik, and D. Del Castillo, “Rabbit antithymocyte globulin versus basiliximab in renal transplantation,” The New England Journal of Medicine, vol. 355, no. 19, pp. 1967–1977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Noël, D. Abramowicz, D. Durand et al., “Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients,” Journal of the American Society of Nephrology, vol. 20, no. 6, pp. 1385–1392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Lebranchu, F. Bridoux, M. Büchler et al., “Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy,” American Journal of Transplantation, vol. 2, no. 1, pp. 48–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Mourad, L. Rostaing, C. Legendre, V. Garrigue, E. Thervet, and D. Durand, “Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids,” Transplantation, vol. 78, no. 4, pp. 584–590, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Ciancio, G. W. Burke, J. J. Gaynor et al., “A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring,” Transplantation, vol. 80, no. 4, pp. 457–465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Abou-Ayache, M. Büchler, P. Lepogamp et al., “CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A,” Nephrology Dialysis Transplantation, vol. 23, no. 6, pp. 2024–2032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Koyawala, J. H. Silber, P. R. Rosenbaum et al., “Comparing outcomes between antibody induction therapies in kidney transplantation,” Journal of the American Society of Nephrology, vol. 28, no. 7, pp. 2188–2200, 2017. View at Publisher · View at Google Scholar · View at Scopus
  56. M. J. Hanaway, E. S. Woodle, S. Mulgaonkar et al., “Alemtuzumab induction in renal transplantation,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1909–1919, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Mourad, V. Garrigue, J.-P. Squifflet et al., “Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression,” Transplantation, vol. 72, no. 6, pp. 1050–1055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Cantarovich, L. Rostaing, N. Kamar et al., “Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction,” Transplant International, vol. 23, no. 3, pp. 313–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Ayasoufi, H. Yu, R. Fan, X. Wang, J. Williams, and A. Valujskikh, “Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactive memory T cells in mice,” American Journal of Transplantation, vol. 13, no. 3, pp. 589–599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. M. S. Zand, T. Vo, J. Huggins et al., “Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways,” Transplantation, vol. 79, no. 11, pp. 1507–1515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Jacobi, S. Beckmann, K. Heller et al., “Deceased donor kidney transplantation in the Eurotransplant Senior Program (ESP): a single-center experience from 2008 to 2013,” Annals of Transplantation, vol. 21, pp. 94–104, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Kanter Berga, A. Sancho Calabuig, E. Gavela Martinez et al., “Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation,” Transplantation Proceedings, vol. 44, no. 9, pp. 2529–2531, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Zhu, G. Chen, W. Zhang et al., “Early de novo donor specific antibody involvement in delayed graft function after kidney transplantation: a report of 2 cases,” Clinical Transplantation, pp. 231–234, 2014. View at Google Scholar
  64. J. Pascual, A. Zuckermann, A. Djamali, A. Hertig, and M. Naesens, “Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation—a review,” Transplantation Reviews, vol. 30, no. 2, pp. 85–91, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. O. Thomusch, M. Wiesener, M. Opgenoorth et al., “Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial,” The Lancet, vol. 388, no. 10063, pp. 3006–3016, 2016. View at Publisher · View at Google Scholar · View at Scopus
  66. N. A. Pilch, D. J. Taber, O. Moussa et al., “Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation,” Annals of Surgery, vol. 259, no. 5, pp. 888–893, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Chapal, Y. Foucher, M. Marguerite et al., “PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial,” Trials, vol. 16, no. 1, article 282, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. R. J. Knight, R. H. Kerman, L. Schoenberg et al., “The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function,” Transplantation, vol. 78, no. 6, pp. 904–910, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Chen, J. Gu, J. Qiu et al., “Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function,” Experimental and Clinical Transplantation, vol. 11, no. 4, pp. 310–314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. H.-F. Huang, J.-Y. Zhou, W.-Q. Xie, J.-Y. Wu, H. Deng, and J.-H. Chen, “Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience,” International Urology and Nephrology, vol. 48, no. 8, pp. 1363–1370, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. S. T. Martin, K. L. Roberts, S. K. Malek et al., “Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal,” Pharmacotherapy, vol. 31, no. 6, pp. 566–573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. A. C. Farney, W. Doares, J. Rogers et al., “A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation,” Transplantation, vol. 88, no. 6, pp. 810–819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. M. L. Mai, W. K. Mai, C. B. Taner, M. B. Prendergast, H. M. Wadei, and T. A. Gonwa, “Antithymocyte globulin induction and rapid steroid taper leads to excellent results in kidney transplantation with donation after cardiac death donors: importance of rejection and delayed graft function,” Transplantation Proceedings, vol. 45, no. 4, pp. 1528–1530, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Popat, A. Syed, C. Puliatti, and R. Cacciola, “Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants,” Transplantation, vol. 97, no. 11, pp. 1161–1165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. W. Peng, G. Liu, W. Xie et al., “Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death,” International Journal of Clinical Practice, no. 183, pp. 23–28, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Mohty, A. Bacigalupo, F. Saliba, A. Zuckermann, E. Morelon, and Y. Lebranchu, “New directions for rabbit antithymocyte globulin (Thymoglobulin®) in solid organ transplants, stem cell transplants and autoimmunity,” Drugs, vol. 74, no. 14, pp. 1605–1634, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. I. A. Agha, J. Rueda, A. Alvarez et al., “Short course induction immunosuppression with thymoglobulin for renal transplant recipients,” Transplantation, vol. 73, no. 3, pp. 473–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. S. J. Patel, R. J. Knight, W. N. Suki et al., “Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age,” Clinical Transplantation, vol. 25, no. 3, pp. E250–E256, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Grafals, B. Smith, N. Murakami et al., “Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study,” PLoS ONE, vol. 9, no. 8, Article ID e104408, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. L. De Pietri, V. Serra, G. Preziosi, G. Rompianesi, and B. Begliomini, “Perioperative effects of high doses of intraoperative thymoglobulin induction in liver transplantation,” World Journal of Transplantation, vol. 5, no. 4, pp. 320–328, 2015. View at Publisher · View at Google Scholar
  81. A. C. Webster, L. P. Ruster, R. McGee et al., “Interleukin 2 receptor antagonists for kidney transplant recipients,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003897, 2010. View at Google Scholar · View at Scopus
  82. A. Hertig and A. Zuckermann, “Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update,” Transplant Immunology, vol. 32, no. 3, pp. 179–187, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Caillard, F. X. Lamy, C. Quelen et al., “Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas,” American Journal of Transplantation, vol. 12, no. 3, pp. 682–693, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. E. C. Hall, E. A. Engels, R. M. Pfeiffer, and D. L. Segev, “Association of antibody induction immunosuppression with cancer after kidney transplantation,” Transplantation, vol. 99, no. 5, pp. 1051–1057, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Cremaschi, R. von Versen, T. Benzing et al., “Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective,” Transplant International, vol. 30, no. 10, pp. 1011–1019, 2017. View at Publisher · View at Google Scholar · View at Scopus